Boston, MA (January 22, 2019): Constant Pharmaceuticals, LLC, a privately held biopharmaceutical company focused on the treatment of stroke recovery and epidermolysis bullosa, today announced that they are changing their name to Constant Therapeutics, LLC. Constant remains committed to the development of TXA127, the lead compound, and is currently planning Phase 2 studies in stroke recovery and recessive dystrophic epidermolysis bullosa (RDEB).
Constant Pharmaceuticals LLC (formerly Tarix Orphan LLC) is a private biopharmaceutical company focused on the treatment of stroke recovery and rare neuromuscular disorders and connective tissue diseases. The company’s lead drug candidate is TXA127, a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1‐7). TX127 has shown therapeutic activity in animal models of RDEB, Duchenne muscular dystrophy (DMD), Limb‐girdle muscular dystrophy (LGMD), congenital muscular dystrophy (MDC1A) and stroke recovery, where the drug is effective with treatment started weeks after the stroke. Constant has broad IP protection for TXA127, and Orphan Drug Designations (ODDs) have been granted for DMD, LGMD, and RDEB in the United States, and for DMD and EB in Europe. For more information on Constant Pharmaceuticals, please visit our website at www.constantpharma.com.
Elizabeth Wagner, Vice President